retatrutide: Retatrutide Dosing Explained: What You Need To Know Phase III retatrutide study demonstrates

Timing of eating and drinking can affect oral formulations, but not injectables

Research presented at the European Congress on Obesity found that people who gradually reduced their dose to zero over an average of nine weeks maintained a stable body weight in the first 26 weeks after tapering

It remains uncertain how widely private insurance plans will cover it

The Potential of Retatrutide Retatrutide leads to 24.2% mean WL at the highest dose after 48 weeks in people with obesity, with no evidence of plateau and up to 26% of participants achieving 30% WL - approaching the efficacy Roux-en-y gastric bypass, one of the most effective BS procedures

Poutoglidou et al

You want to talk to the consumer about what it is that theyre looking for